Women, as well as older adults, people with diabetes, and post-cardiac transplant patients, are less likely to experience textbook chest pressure and are more likely to have subtle warning signs like extreme fatigue, shortness of breath, or nausea, which can lead to dangerous delays in seeking care
Some employers are exploring options such as HRA accounts to subsidize the cost of the medication while limiting their financial exposure
Prim Care Companion CNS Disord 2025;27(3):24nr03855 Author Affiliations: PPD, Part of Thermo Fisher, Cypress, Texas (Khan)
FDA has approved Foundayo (orforglipron), developed by Eli Lilly and Company, as the first oral non-peptide GLP-1 receptor agonist for chronic weight management